Can India's Syngene best WuXi?
This article was originally published in Scrip
Executive Summary
India's Syngene International's initial public offer (IPO) opened for subscription on 27 July, amid generally encouraging reviews and comparisons with China's WuXi PharmaTech. Syngene is the research services arm of Biocon.